Mark A. Oyama
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Mark A. Oyama has a total of 339 co-authors. Here are the top co-authors by number of shared publications:
Kerry A. Loughran
School of Veterinary Medicine, University of Pennsylvania Department of Clinical Sciences and Advanced Medicine Philadelphia, Pennsylvania
12 shared publicationsÉva Larouche-Lebel
School of Veterinary Medicine, University of Pennsylvania Department of Clinical Sciences and Advanced Medicine Philadelphia, Pennsylvania
8 shared publications- Anna R. Gelzer
School of Veterinary Medicine, University of Pennsylvania Department of Clinical Studies and Advanced Medicine Philadelphia, Pennsylvania
7 shared publications - Jens Häggström
Department of Clinical Sciences Swedish University of Agricultural Sciences Uppsala Sweden
6 shared publications Terry Huh
School of Veterinary Medicine, University of Pennsylvania Department of Clinical Sciences and Advanced Medicine Philadelphia, Pennsylvania
6 shared publicationsG.E. Singletary
Department of Clinical Studies School of Veterinary Medicine University of Pennsylvania Philadelphia PA
5 shared publications
Latest Publications
- Open Access
- 4 May 2026
- Published by Oxford University Press (OUP) in Journal of Veterinary Internal Medicine
- Vol. 40 (3)
Urine sodium concentration and diuretic responsiveness in dogs receiving orally administered loop diuretics for chronic congestive heart failure
Background: Urine sodium concentration (uNa) measures diuretic responsiveness (DR) in acute congestive heart failure (CHF). In humans with chronic CHF receiving loop diuretics PO, low uNa is associated with rehospitalization and mortality. DR in dogs with chronic CHF is poorly understood. Hypothesis/Objectives: Measure uNa and pharmacologic and pathophysiologic variables in dogs receiving loop diuretics PO for chronic CHF. Animals: Eleven client-owned dogs. Methods: Prospective longitudinal observational study. Owners collected multiple convenience urine samples over 5 days. Associations between urine electrolyte, creatinine, and loop diuretic concentrations, dose and duration of PO diuretic treatment, and time from previous diuretic administration or feeding were examined using mixed effects linear regression. Results: A total of 189 samples were collected. Median uNa was 27 mmol/L (IQR, 10-61 mmol/L). Dose and time from previous PO diuretic or feeding were not significantly associated with uNa. In 5 of 11 (45%) dogs, uNa < 70 mmol/L was observed consistently and indicative of low DR. Urine diuretic concentration was not significantly associated with uNa (β, 0.29; 95% CI, −0.03 to 0.61; P = .08) or diuretic dose, duration of treatment, or time from last PO diuretic or feeding. Individual variability was high. Observed patterns of uNa, diuretic dose, and urine diuretic concentration suggested potential causes of low DR. Conclusions and clinical importance: Measurement of uNa and diuretic concentration identifies dogs with low natriuresis, which is not predicted by diuretic dose or duration. Observation of uNa patterns generates hypotheses regarding potential causes of low DR that warrant confirmation in larger studies.
- 4 May 2026
- Published by Oxford University Press (OUP) in Journal of Veterinary Internal Medicine
- Vol. 40 (3)
Open AccessUrine sodium concentration and diuretic responsiveness in dogs receiving orally administered loop diuretics for chronic congestive heart failure
Background: Urine sodium concentration (uNa) measures diuretic responsiveness (DR) in acute congestive heart failure (CHF). In humans with chronic CHF receiving loop diuretics PO, low uNa is associated with rehospitalization and mortality. DR in dogs with chronic CHF is poorly understood. Hypothesis/Objectives: Measure uNa and pharmacologic and pathophysiologic variables in dogs receiving loop diuretics PO for chronic CHF. Animals: Eleven client-owned dogs. Methods: Prospective longitudinal observational study. Owners collected multiple convenience urine samples over 5 days. Associations between urine electrolyte, creatinine, and loop diuretic concentrations, dose and duration of PO diuretic treatment, and time from previous diuretic administration or feeding were examined using mixed effects linear regression. Results: A total of 189 samples were collected. Median uNa was 27 mmol/L (IQR, 10-61 mmol/L). Dose and time from previous PO diuretic or feeding were not significantly associated with uNa. In 5 of 11 (45%) dogs, uNa < 70 mmol/L was observed consistently and indicative of low DR. Urine diuretic concentration was not significantly associated with uNa (β, 0.29; 95% CI, −0.03 to 0.61; P = .08) or diuretic dose, duration of treatment, or time from last PO diuretic or feeding. Individual variability was high. Observed patterns of uNa, diuretic dose, and urine diuretic concentration suggested potential causes of low DR. Conclusions and clinical importance: Measurement of uNa and diuretic concentration identifies dogs with low natriuresis, which is not predicted by diuretic dose or duration. Observation of uNa patterns generates hypotheses regarding potential causes of low DR that warrant confirmation in larger studies.
- Open Access
- 2 March 2026
- Published by Oxford University Press (OUP) in Journal of Veterinary Internal Medicine
- Vol. 40 (2)
Effect of the sodium glucose transporter-2 inhibitor dapagliflozin on urine and blood biomarkers in dogs with heart disease
Background: Sodium-glucose transport 2 inhibitors (SGLT2i) decrease morbidity and mortality in human patients with heart failure through a variety of proposed mechanisms, including natriuresis and glucosuria. The effects of SGLT2i on urine sodium (uNa) and urine glucose (uGlu) concentrations in dogs with heart disease have not been evaluated. Hypothesis/Objectives: Administration of the SGLT2i dapagliflozin to dogs with heart disease will be well-tolerated and increase uNa and uGlu concentrations. Laboratory results and biomarker assays will provide insight into potential mechanisms of action. Animals: Ten client-owned dogs with heart disease with or without congestive heart failure. Methods: Prospective multicenter open-label uncontrolled study. Blood and urine biochemistry and oxidative and inflammatory biomarkers were evaluated at baseline and 5-7 days after 0.45-1 mg/kg/day PO dapagliflozin. Results: A treatment effect was observed for uGlu (baseline, 14 mg/dL; IQR, 2-19 mg/dL; treatment effect +3102 mg/dL; IQR, 2390-4387 mg/dL; P = .002) but not for uNa (baseline, 75 mmol/L; IQR, 28-129 mmol/L; treatment effect, −41 mmol/L; IQR, −96-21 mmol/L; P = .12). Serum total thiol concentration increased (baseline, 145 μmol/L; SD, 32 μmol/L; treatment effect, +7 μmol/L; SD, 9 μmol/L; P = .04), suggesting an antioxidative effect. Serious adverse effects, including hypoglycemia or ketoacidosis, were not observed. Conclusions and clinical importance: Short-term PO dapagliflozin was well-tolerated and associated with glucosuria but not natriuresis. Clinical benefit of SGLT2i in dogs with heart disease might include non-natriuretic mechanisms, such as anti-inflammatory, antioxidative, or metabolic effects.
- 2 March 2026
- Published by Oxford University Press (OUP) in Journal of Veterinary Internal Medicine
- Vol. 40 (2)
Open AccessEffect of the sodium glucose transporter-2 inhibitor dapagliflozin on urine and blood biomarkers in dogs with heart disease
Background: Sodium-glucose transport 2 inhibitors (SGLT2i) decrease morbidity and mortality in human patients with heart failure through a variety of proposed mechanisms, including natriuresis and glucosuria. The effects of SGLT2i on urine sodium (uNa) and urine glucose (uGlu) concentrations in dogs with heart disease have not been evaluated. Hypothesis/Objectives: Administration of the SGLT2i dapagliflozin to dogs with heart disease will be well-tolerated and increase uNa and uGlu concentrations. Laboratory results and biomarker assays will provide insight into potential mechanisms of action. Animals: Ten client-owned dogs with heart disease with or without congestive heart failure. Methods: Prospective multicenter open-label uncontrolled study. Blood and urine biochemistry and oxidative and inflammatory biomarkers were evaluated at baseline and 5-7 days after 0.45-1 mg/kg/day PO dapagliflozin. Results: A treatment effect was observed for uGlu (baseline, 14 mg/dL; IQR, 2-19 mg/dL; treatment effect +3102 mg/dL; IQR, 2390-4387 mg/dL; P = .002) but not for uNa (baseline, 75 mmol/L; IQR, 28-129 mmol/L; treatment effect, −41 mmol/L; IQR, −96-21 mmol/L; P = .12). Serum total thiol concentration increased (baseline, 145 μmol/L; SD, 32 μmol/L; treatment effect, +7 μmol/L; SD, 9 μmol/L; P = .04), suggesting an antioxidative effect. Serious adverse effects, including hypoglycemia or ketoacidosis, were not observed. Conclusions and clinical importance: Short-term PO dapagliflozin was well-tolerated and associated with glucosuria but not natriuresis. Clinical benefit of SGLT2i in dogs with heart disease might include non-natriuretic mechanisms, such as anti-inflammatory, antioxidative, or metabolic effects.
- Open Access
Plasma Cardiac Troponin-I Concentration in Normal Horses and in Horses with Cardiac Abnormalities
Cardiac troponin-I (cTnI) is a highly sensitive and specific marker of myocardial injury detectable in plasma by immunoassay techniques. Inclusion criteria over a 3-year period required a diagnosis of cardiac disease accompanied by electrocardiographic (ECG) and cardiac ultrasound examinations (n = 23) in adult horses (≥2 years of age). A second group of normal adult ponies (n = 12) was studied as a reference group. Heparinized jugular venous blood samples were collected and centrifuged within 30 min, and the plasma was separated and frozen at −70 °C for subsequent batched cTnI analysis. The lower limit of detection was 0.01 ng/mL, and the upper limit was 100 ng/mL of plasma. Normal equine plasma cTnI concentrations ranged from 0.01 to 0.03 ng/mL (n = 12). Horses with non-arrhythmogenic murmurs (n = 4) included tricuspid (0.05 ng/mL cTnI), mitral (0.07), and aortic insufficiencies (0.01, 0.02). Horses with benign atrial fibrillation (n = 8) had a cTnI range of 100 ng/mL. Horses with ventricular arrhythmias but no documentation of myocardial toxicity (n = 3) had cTnI concentrations of 0.34, 0.46, and 80.42 ng/mL. When grouped by arrhythmia type and compared using the Mann–Whitney Rank Sum Test, the median ventricular arrhythmia cTnI (0.40 ng/mL) was significantly higher than the median atrial fibrillation cTnI (0.04 ng/mL, p < 0.001). It was concluded that horses with myocardial toxicities and ventricular arrhythmias often had severe elevations in plasma cTnI.
Open AccessPlasma Cardiac Troponin-I Concentration in Normal Horses and in Horses with Cardiac Abnormalities
Cardiac troponin-I (cTnI) is a highly sensitive and specific marker of myocardial injury detectable in plasma by immunoassay techniques. Inclusion criteria over a 3-year period required a diagnosis of cardiac disease accompanied by electrocardiographic (ECG) and cardiac ultrasound examinations (n = 23) in adult horses (≥2 years of age). A second group of normal adult ponies (n = 12) was studied as a reference group. Heparinized jugular venous blood samples were collected and centrifuged within 30 min, and the plasma was separated and frozen at −70 °C for subsequent batched cTnI analysis. The lower limit of detection was 0.01 ng/mL, and the upper limit was 100 ng/mL of plasma. Normal equine plasma cTnI concentrations ranged from 0.01 to 0.03 ng/mL (n = 12). Horses with non-arrhythmogenic murmurs (n = 4) included tricuspid (0.05 ng/mL cTnI), mitral (0.07), and aortic insufficiencies (0.01, 0.02). Horses with benign atrial fibrillation (n = 8) had a cTnI range of 100 ng/mL. Horses with ventricular arrhythmias but no documentation of myocardial toxicity (n = 3) had cTnI concentrations of 0.34, 0.46, and 80.42 ng/mL. When grouped by arrhythmia type and compared using the Mann–Whitney Rank Sum Test, the median ventricular arrhythmia cTnI (0.40 ng/mL) was significantly higher than the median atrial fibrillation cTnI (0.04 ng/mL, p < 0.001). It was concluded that horses with myocardial toxicities and ventricular arrhythmias often had severe elevations in plasma cTnI.
- Open Access
- 5 November 2024
- Published by Oxford University Press (OUP) in ESC Heart Failure
- Vol. 12 (2) , 1256-1270
Metabolic Abnormalities and Reprogramming in Cats with Naturally Occurring Hypertrophic Cardiomyopathy
Background and aims: The heart is a metabolic organ rich in mitochondria. The failing heart reprograms to utilize different energy substrates, which increase its oxygen consumption. These adaptive changes contribute to increased oxidative stress. Hypertrophic cardiomyopathy (HCM) is a common heart condition, affecting approximately 15% of the general cat population. Feline HCM shares phenotypical and genotypical similarities with human HCM, but the disease mechanisms for both species are incompletely understood. Our goal was to characterize global changes in metabolome between healthy control cats and cats with different stages of HCM. Methods: Serum samples from 83 cats, the majority (70/83) of which were domestic shorthair and included 23 healthy control cats, 31 and 12 preclinical cats with American College of Veterinary Internal Medicine (ACVIM) stages B1 and B2, respectively, and 17 cats with history of clinical heart failure or arterial thromboembolism (ACVIM stage C), were collected for untargeted metabolomic analysis. Multiple linear regression adjusted for age, sex and body weight was applied to compare between control and across HCM groups. Results: Our study identified 1253 metabolites, of which 983 metabolites had known identities. Statistical analysis identified 167 metabolites that were significantly different among groups (adjusted P < 0.1). About half of the differentially identified metabolites were lipids, including glycerophospholipids, sphingolipids and cholesterol. Serum concentrations of free fatty acids, 3-hydroxy fatty acids and acylcarnitines were increased in HCM groups compared with control group. The levels of creatine phosphate and multiple Krebs cycle intermediates, including succinate, aconitate and α-ketoglutarate, also accumulated in the circulation of HCM cats. In addition, serum levels of nicotinamide and tryptophan, precursors for de novo NAD+ biosynthesis, were reduced in HCM groups versus control group. Glutathione metabolism was altered. Serum levels of cystine, the oxidized form of cysteine and cysteine-glutathione disulfide, were elevated in the HCM groups, indicative of heightened oxidative stress. Further, the level of ophthalmate, an endogenous glutathione analog and competitive inhibitor, was increased by more than twofold in HCM groups versus control group. Finally, several uremic toxins, including guanidino compounds and protein bound putrescine, accumulated in the circulation of HCM cats. Conclusions: Our study provided evidence of deranged energy metabolism, altered glutathione homeostasis and impaired renal uremic toxin excretion. Altered lipid metabolism suggested perturbed structure and function of cardiac sarcolemma membrane and lipid signalling.
- 5 November 2024
- Published by Oxford University Press (OUP) in ESC Heart Failure
- Vol. 12 (2) , 1256-1270
Open AccessMetabolic Abnormalities and Reprogramming in Cats with Naturally Occurring Hypertrophic Cardiomyopathy
Background and aims: The heart is a metabolic organ rich in mitochondria. The failing heart reprograms to utilize different energy substrates, which increase its oxygen consumption. These adaptive changes contribute to increased oxidative stress. Hypertrophic cardiomyopathy (HCM) is a common heart condition, affecting approximately 15% of the general cat population. Feline HCM shares phenotypical and genotypical similarities with human HCM, but the disease mechanisms for both species are incompletely understood. Our goal was to characterize global changes in metabolome between healthy control cats and cats with different stages of HCM. Methods: Serum samples from 83 cats, the majority (70/83) of which were domestic shorthair and included 23 healthy control cats, 31 and 12 preclinical cats with American College of Veterinary Internal Medicine (ACVIM) stages B1 and B2, respectively, and 17 cats with history of clinical heart failure or arterial thromboembolism (ACVIM stage C), were collected for untargeted metabolomic analysis. Multiple linear regression adjusted for age, sex and body weight was applied to compare between control and across HCM groups. Results: Our study identified 1253 metabolites, of which 983 metabolites had known identities. Statistical analysis identified 167 metabolites that were significantly different among groups (adjusted P < 0.1). About half of the differentially identified metabolites were lipids, including glycerophospholipids, sphingolipids and cholesterol. Serum concentrations of free fatty acids, 3-hydroxy fatty acids and acylcarnitines were increased in HCM groups compared with control group. The levels of creatine phosphate and multiple Krebs cycle intermediates, including succinate, aconitate and α-ketoglutarate, also accumulated in the circulation of HCM cats. In addition, serum levels of nicotinamide and tryptophan, precursors for de novo NAD+ biosynthesis, were reduced in HCM groups versus control group. Glutathione metabolism was altered. Serum levels of cystine, the oxidized form of cysteine and cysteine-glutathione disulfide, were elevated in the HCM groups, indicative of heightened oxidative stress. Further, the level of ophthalmate, an endogenous glutathione analog and competitive inhibitor, was increased by more than twofold in HCM groups versus control group. Finally, several uremic toxins, including guanidino compounds and protein bound putrescine, accumulated in the circulation of HCM cats. Conclusions: Our study provided evidence of deranged energy metabolism, altered glutathione homeostasis and impaired renal uremic toxin excretion. Altered lipid metabolism suggested perturbed structure and function of cardiac sarcolemma membrane and lipid signalling.
- Open Access
- 1 November 2024
- Published by Oxford University Press (OUP) in Journal of Veterinary Internal Medicine
- Vol. 38 (6) , 3016-3024
Observed and expected reliability of echocardiographic volumetric methods and critical change values for quantification of mitral regurgitant fraction in dogs
Background: Reliability of echocardiographic calculations for stroke volume and mitral regurgitant fraction (RFMR) are affected by observer variability and lack of a gold standard. Variability is used to calculate critical change values (CCVs) that are thresholds representing real change in a measure not associated with observer variability. Hypothesis: Observed intra- and interobserver accuracy and variability in healthy dogs help model CCV for RFMR. Animals: Reliability cohort of 34 healthy dogs; allometric scaling cohort of 99 dogs with heart disease and 25 healthy dogs. Methods: Accuracy, variability, and CCV of 2 observers using geometric and flow-based echocardiography were prospectively compared against a standard of RFMR = 0% and extrapolated across a range of expected RFMR values in the reliability cohort partly derived from cardiac dimensions predicted by the allometric cohort. Results: Accuracy of methods to determine RFMR in descending order was 4-chamber bullet (Bullet4CH), mitral inflow, cube formula, and Simpson's method of disks. Intraobserver variability was relatively high. The CCV for RFMR ranged from 28% to 88% and was inversely related to RFMR when extrapolated for use in affected dogs. For both observers, the Bullet4CH method had the lowest intraobserver CCV (Operator 1:28%, Operator 2:41%). Interobserver strength of agreement was low with intraclass correlation coefficients ranging from 0.210 to 0.413. Conclusions and Clinical Importance: Echocardiographic volumetric methods used to calculate stroke volume and RFMR have low accuracy and high variability in healthy dogs. Extrapolation of observed CCV to a range of expected RFMR suggests observers and methods are not interchangeable and variability might hinder routine clinical usage. Individual observers should be aware of their own variability and CCV.
- 1 November 2024
- Published by Oxford University Press (OUP) in Journal of Veterinary Internal Medicine
- Vol. 38 (6) , 3016-3024
Open AccessObserved and expected reliability of echocardiographic volumetric methods and critical change values for quantification of mitral regurgitant fraction in dogs
Background: Reliability of echocardiographic calculations for stroke volume and mitral regurgitant fraction (RFMR) are affected by observer variability and lack of a gold standard. Variability is used to calculate critical change values (CCVs) that are thresholds representing real change in a measure not associated with observer variability. Hypothesis: Observed intra- and interobserver accuracy and variability in healthy dogs help model CCV for RFMR. Animals: Reliability cohort of 34 healthy dogs; allometric scaling cohort of 99 dogs with heart disease and 25 healthy dogs. Methods: Accuracy, variability, and CCV of 2 observers using geometric and flow-based echocardiography were prospectively compared against a standard of RFMR = 0% and extrapolated across a range of expected RFMR values in the reliability cohort partly derived from cardiac dimensions predicted by the allometric cohort. Results: Accuracy of methods to determine RFMR in descending order was 4-chamber bullet (Bullet4CH), mitral inflow, cube formula, and Simpson's method of disks. Intraobserver variability was relatively high. The CCV for RFMR ranged from 28% to 88% and was inversely related to RFMR when extrapolated for use in affected dogs. For both observers, the Bullet4CH method had the lowest intraobserver CCV (Operator 1:28%, Operator 2:41%). Interobserver strength of agreement was low with intraclass correlation coefficients ranging from 0.210 to 0.413. Conclusions and Clinical Importance: Echocardiographic volumetric methods used to calculate stroke volume and RFMR have low accuracy and high variability in healthy dogs. Extrapolation of observed CCV to a range of expected RFMR suggests observers and methods are not interchangeable and variability might hinder routine clinical usage. Individual observers should be aware of their own variability and CCV.
- Open Access
- 1 July 2024
- Published by Oxford University Press (OUP) in Journal of Veterinary Internal Medicine
- Vol. 38 (4) , 2076-2088
Longitudinal analysis of echocardiographic and cardiac biomarker variables in dogs with atrial fibrillation: The optimal rate control in dogs with atrial fibrillation II study
Background: Rate control (RC; meanHRHolter ≤ 125 bpm) increases survival in dogs with atrial fibrillation (AF). The mechanisms remain unclear. Hypothesis/Objectives: Investigate echocardiographic and biomarker differences between RC and non-RC (NRC) dogs. Determine if changes post-anti-arrhythmic drugs (AAD) predict successful RC in subsequent Holter monitoring. Evaluate if early vs late RC affects survival. Animals: Fifty-two dogs with AF. Methods: Holter-derived mean heart rate, echocardiographic and biomarker variables from dogs receiving AAD were analyzed prospectively at each re-evaluation and grouped into RC or NRC. The primary endpoint was successful RC. Between group comparisons of absolute values, magnitude of change from admission to re-evaluations and end of study were performed using Mann-Whitney tests or unpaired t-tests. Logistic regression explored variables associated with inability to achieve RC at subsequent visits. Kaplan-Meier survival analysis was used to compare survival time of early vs late RC. Results: At visit 2, 11/52 dogs were RC; at visit 3, 14/52 were RC; and at visit 4, 4/52 were RC. At the end of study, 25/52 remained NRC. At visit 2, both groups had increased cardiac dimensions, but NRC dogs had larger dimensions; biomarkers did not differ. At the end of study, RC showed decreased cardiac dimensions and end-terminal pro-brain natriuretic peptide (NT-proBNP) compared with NRC. No variables were useful at predicting RC success in subsequent visits. Survival analysis found no differences between early vs late RC. Conclusions and Clinical Importance: The RC dogs had decreased cardiac dimensions and NT-proBNP, suggesting HR-mediated reverse-remodeling might benefit survival, even with delayed RC achievement. Pursuit of RC is crucial despite initial failures.
- 1 July 2024
- Published by Oxford University Press (OUP) in Journal of Veterinary Internal Medicine
- Vol. 38 (4) , 2076-2088
Open AccessLongitudinal analysis of echocardiographic and cardiac biomarker variables in dogs with atrial fibrillation: The optimal rate control in dogs with atrial fibrillation II study
Background: Rate control (RC; meanHRHolter ≤ 125 bpm) increases survival in dogs with atrial fibrillation (AF). The mechanisms remain unclear. Hypothesis/Objectives: Investigate echocardiographic and biomarker differences between RC and non-RC (NRC) dogs. Determine if changes post-anti-arrhythmic drugs (AAD) predict successful RC in subsequent Holter monitoring. Evaluate if early vs late RC affects survival. Animals: Fifty-two dogs with AF. Methods: Holter-derived mean heart rate, echocardiographic and biomarker variables from dogs receiving AAD were analyzed prospectively at each re-evaluation and grouped into RC or NRC. The primary endpoint was successful RC. Between group comparisons of absolute values, magnitude of change from admission to re-evaluations and end of study were performed using Mann-Whitney tests or unpaired t-tests. Logistic regression explored variables associated with inability to achieve RC at subsequent visits. Kaplan-Meier survival analysis was used to compare survival time of early vs late RC. Results: At visit 2, 11/52 dogs were RC; at visit 3, 14/52 were RC; and at visit 4, 4/52 were RC. At the end of study, 25/52 remained NRC. At visit 2, both groups had increased cardiac dimensions, but NRC dogs had larger dimensions; biomarkers did not differ. At the end of study, RC showed decreased cardiac dimensions and end-terminal pro-brain natriuretic peptide (NT-proBNP) compared with NRC. No variables were useful at predicting RC success in subsequent visits. Survival analysis found no differences between early vs late RC. Conclusions and Clinical Importance: The RC dogs had decreased cardiac dimensions and NT-proBNP, suggesting HR-mediated reverse-remodeling might benefit survival, even with delayed RC achievement. Pursuit of RC is crucial despite initial failures.
- Open Access
- 1 May 2024
- Published by Oxford University Press (OUP) in Journal of Veterinary Internal Medicine
- Vol. 38 (3) , 1325-1333
Utility of focused cardiac ultrasonography training in veterinary students to differentiate stages of subclinical myxomatous mitral valve disease in dogs
Background: Differentiation of the subclinical phases of myxomatous mitral valve disease (MMVD) in dogs relies heavily on echocardiography. Focused cardiac ultrasonography (FCU) is a point-of-care technique that can assess heart size. Hypothesis/Objectives: Veterinary students trained in FCU can differentiate dogs with subclinical MMVD based on left ventricular (LV) and left atrial (LA) dimensions. Animals: Forty-eight dogs with subclinical MMVD. Methods: Veterinary students were trained to measure LV dimension and LA-to-aortic root dimension ratio (LA : Ao) using FCU. Dogs were categorized into 2 cohorts based on whether or not the LV normalized internal diastolic dimension was ≥1.7 and LA : Ao was ≥1.6. Agreement between FCU and echocardiographic studies performed by cardiologists was evaluated. Results: One-hundred and forty-six FCU examinations were performed by 58 veterinary students on 48 dogs. Overall agreement between students and cardiologists was moderate (Fleiss' kappa, 0.54; 95% confidence interval [CI], 0.39-0.69; P < .001). Percentage accuracy in observations with heart dimensions less than the cutoffs (86/89, 97%) was significantly higher than in observations in with larger hearts (31/57, 54%; P < .001). Agreement increased from moderate to good as heart sizes became more extreme. Degree of confidence by students in performing FCU was significantly higher at the end vs start of the study. Conclusions and Clinical Importance: Categorization of dogs with subclinical MMVD by veterinary students using FCU was associated with moderate to good agreement with echocardiography. Focused cardiac ultrasonography is a point-of-care method that can help assess clinical stage in dogs with subclinical MMVD.
- 1 May 2024
- Published by Oxford University Press (OUP) in Journal of Veterinary Internal Medicine
- Vol. 38 (3) , 1325-1333
Open AccessUtility of focused cardiac ultrasonography training in veterinary students to differentiate stages of subclinical myxomatous mitral valve disease in dogs
Background: Differentiation of the subclinical phases of myxomatous mitral valve disease (MMVD) in dogs relies heavily on echocardiography. Focused cardiac ultrasonography (FCU) is a point-of-care technique that can assess heart size. Hypothesis/Objectives: Veterinary students trained in FCU can differentiate dogs with subclinical MMVD based on left ventricular (LV) and left atrial (LA) dimensions. Animals: Forty-eight dogs with subclinical MMVD. Methods: Veterinary students were trained to measure LV dimension and LA-to-aortic root dimension ratio (LA : Ao) using FCU. Dogs were categorized into 2 cohorts based on whether or not the LV normalized internal diastolic dimension was ≥1.7 and LA : Ao was ≥1.6. Agreement between FCU and echocardiographic studies performed by cardiologists was evaluated. Results: One-hundred and forty-six FCU examinations were performed by 58 veterinary students on 48 dogs. Overall agreement between students and cardiologists was moderate (Fleiss' kappa, 0.54; 95% confidence interval [CI], 0.39-0.69; P < .001). Percentage accuracy in observations with heart dimensions less than the cutoffs (86/89, 97%) was significantly higher than in observations in with larger hearts (31/57, 54%; P < .001). Agreement increased from moderate to good as heart sizes became more extreme. Degree of confidence by students in performing FCU was significantly higher at the end vs start of the study. Conclusions and Clinical Importance: Categorization of dogs with subclinical MMVD by veterinary students using FCU was associated with moderate to good agreement with echocardiography. Focused cardiac ultrasonography is a point-of-care method that can help assess clinical stage in dogs with subclinical MMVD.
- Open Access
- 1 May 2024
- Published by Oxford University Press (OUP) in Journal of Veterinary Internal Medicine
- Vol. 38 (3) , 1353-1358
Effect of sodium-glucose cotransporter 2 inhibitor canagliflozin on interstitial glucose concentration in insulin-treated diabetic dogs
Background: The utility of sodium-glucose cotransporter 2 inhibitors (SGLT2i) has not been reported in insulin-treated diabetic dogs. Hypothesis: Canagliflozin, a PO-administered SGLT2i, decreases interstitial glucose concentration (IG) in insulin-treated diabetic dogs. Animals: Five insulin-treated diabetic dogs. Methods: Uncontrolled open label longitudinal study. Canagliflozin (2-4 mg/kg/day PO) was added to an unchanged insulin dose for 7 days. Fractional excretion of glucose was calculated by dividing the product of urine glucose and serum creatinine concentrations by the product of serum glucose and urine creatinine concentrations. Hypoglycemia was defined as IG <60 mg/dL. Results: Median IG in 2869 measurements obtained while dogs were treated with insulin and canagliflozin was 87 mg/dL (range, 40-500 mg/dL) and was significantly lower than median IG in 1426 measurements obtained while dogs were treated with insulin alone (212 mg/dL; range, 41-500 mg/dL; P < .001). Median fractional excretion of glucose when dogs were treated with insulin and canagliflozin was 1.1% (range, 0.9%-2.0%), significantly higher than when dogs were treated with insulin alone (0.3%; range, 0.01%-1.0%; P = .04). The frequency of hypoglycemia was higher in dogs treated with insulin and canagliflozin (544 of 2869 IG measurements, 19%) compared with the frequency of hypoglycemia in dogs treated with insulin alone (52 of 1426 IG measurements, 4%; P < .001). Conclusions and Clinical Importance: Canagliflozin may have a role in improving glycemic control in insulin-treated diabetic dogs, but the dose of insulin should be decreased when adding canagliflozin to insulin treatment.
- 1 May 2024
- Published by Oxford University Press (OUP) in Journal of Veterinary Internal Medicine
- Vol. 38 (3) , 1353-1358
Open AccessEffect of sodium-glucose cotransporter 2 inhibitor canagliflozin on interstitial glucose concentration in insulin-treated diabetic dogs
Background: The utility of sodium-glucose cotransporter 2 inhibitors (SGLT2i) has not been reported in insulin-treated diabetic dogs. Hypothesis: Canagliflozin, a PO-administered SGLT2i, decreases interstitial glucose concentration (IG) in insulin-treated diabetic dogs. Animals: Five insulin-treated diabetic dogs. Methods: Uncontrolled open label longitudinal study. Canagliflozin (2-4 mg/kg/day PO) was added to an unchanged insulin dose for 7 days. Fractional excretion of glucose was calculated by dividing the product of urine glucose and serum creatinine concentrations by the product of serum glucose and urine creatinine concentrations. Hypoglycemia was defined as IG <60 mg/dL. Results: Median IG in 2869 measurements obtained while dogs were treated with insulin and canagliflozin was 87 mg/dL (range, 40-500 mg/dL) and was significantly lower than median IG in 1426 measurements obtained while dogs were treated with insulin alone (212 mg/dL; range, 41-500 mg/dL; P < .001). Median fractional excretion of glucose when dogs were treated with insulin and canagliflozin was 1.1% (range, 0.9%-2.0%), significantly higher than when dogs were treated with insulin alone (0.3%; range, 0.01%-1.0%; P = .04). The frequency of hypoglycemia was higher in dogs treated with insulin and canagliflozin (544 of 2869 IG measurements, 19%) compared with the frequency of hypoglycemia in dogs treated with insulin alone (52 of 1426 IG measurements, 4%; P < .001). Conclusions and Clinical Importance: Canagliflozin may have a role in improving glycemic control in insulin-treated diabetic dogs, but the dose of insulin should be decreased when adding canagliflozin to insulin treatment.
- Open Access
- 1 January 2024
- Published by Oxford University Press (OUP) in Journal of Veterinary Internal Medicine
- Vol. 38 (1) , 71-80
Urine sodium concentration after intravenous furosemide in dogs with acute congestive heart failure and correlation with treatment efficacy
Background: Poor natriuresis is a potential marker of diuretic resistance in dogs with acute congestive heart failure (CHF) but little is known about the relationship between urine sodium concentration (uNa) and frequency of successful decongestion. Supplemental O2 is a common treatment in dogs with severe CHF. The time from start to discontinuation of supplemental O2 therapy (DCSO2) typically reflects the time course and ease of decongestion. Hypothesis/Objectives: Urine Na concentration after IV administration of furosemide will be correlated with duration of treatment with supplemental O2 (timeO2) and the cumulative frequency of successful DCSO2 during hospitalization. Animals: Fifty-one dogs with acute CHF. Methods: Retrospective observational single center study. Results: Dogs with low uNa had significantly longer mean timeO2 than dogs with high uNa (uNa <87 mmol/L, 24.2 ± 2.6 hours vs uNa ≥87 mmol/L, 16.6 ± 1.7 hours; P = .02). Low uNa was correlated with lower cumulative frequency of DCSO2 (12 hour, 28%; 24 hour, 42%; 36 hour, 73%) compared to high uNa (12 hour, 28%; 24 hour, 88%; 36 hour, 96%; P = .005). History of PO loop diuretics, low serum chloride concentration (sCl), and high PCV were associated with low uNa. Urine Na concentration outperformed other metrics of diuretic responsiveness including weight loss. Conclusions and Clinical Importance: Urine Na concentration after IV furosemide predicted timeO2 and cumulative frequency of DCSO2 in dogs with acute CHF, which likely reflects important aspects of diuretic responsiveness. Urine Na can assess diuretic responsiveness and treatment efficacy in dogs with CHF.
- 1 January 2024
- Published by Oxford University Press (OUP) in Journal of Veterinary Internal Medicine
- Vol. 38 (1) , 71-80
Open AccessUrine sodium concentration after intravenous furosemide in dogs with acute congestive heart failure and correlation with treatment efficacy
Background: Poor natriuresis is a potential marker of diuretic resistance in dogs with acute congestive heart failure (CHF) but little is known about the relationship between urine sodium concentration (uNa) and frequency of successful decongestion. Supplemental O2 is a common treatment in dogs with severe CHF. The time from start to discontinuation of supplemental O2 therapy (DCSO2) typically reflects the time course and ease of decongestion. Hypothesis/Objectives: Urine Na concentration after IV administration of furosemide will be correlated with duration of treatment with supplemental O2 (timeO2) and the cumulative frequency of successful DCSO2 during hospitalization. Animals: Fifty-one dogs with acute CHF. Methods: Retrospective observational single center study. Results: Dogs with low uNa had significantly longer mean timeO2 than dogs with high uNa (uNa <87 mmol/L, 24.2 ± 2.6 hours vs uNa ≥87 mmol/L, 16.6 ± 1.7 hours; P = .02). Low uNa was correlated with lower cumulative frequency of DCSO2 (12 hour, 28%; 24 hour, 42%; 36 hour, 73%) compared to high uNa (12 hour, 28%; 24 hour, 88%; 36 hour, 96%; P = .005). History of PO loop diuretics, low serum chloride concentration (sCl), and high PCV were associated with low uNa. Urine Na concentration outperformed other metrics of diuretic responsiveness including weight loss. Conclusions and Clinical Importance: Urine Na concentration after IV furosemide predicted timeO2 and cumulative frequency of DCSO2 in dogs with acute CHF, which likely reflects important aspects of diuretic responsiveness. Urine Na can assess diuretic responsiveness and treatment efficacy in dogs with CHF.
- Open Access
- 1 July 2023
- Published by Oxford University Press (OUP) in Journal of Veterinary Internal Medicine
- Vol. 37 (4) , 1323-1330
Effect of a specially formulated diet on progression of heart enlargement in dogs with subclinical degenerative mitral valve disease
Background: Previous studies in dogs with degenerative mitral valve disease (DMVD) have identified altered myocardial energy metabolism and oxidation, which might contribute to cardiac hypertrophy. Diets rich in medium chain fatty acids and antioxidants are a potential means of treatment. A previous clinical study found significantly smaller left atrial diameter (LAD) and left atrium-to-aorta diameter ratio (LA : Ao) in dogs with subclinical DMVD fed a specially formulated diet vs control diet for 6 months. Hypothesis/Objectives: A specially formulated diet will slow or arrest left heart enlargement in dogs with subclinical DMVD over 365 days. Animals: One hundred twenty-seven dogs with unmedicated subclinical DMVD; 101 dogs in the per protocol cohort. Methods: Randomized double-blinded controlled multicenter clinical trial. Results: The study's primary composite outcome measure was the sum of percentage change in LAD and left ventricular internal dimension at end-diastole (LVIDd) at day 365. In the per protocol cohort, the outcome measure increased by 8.0% (95% confidence interval [CI], 2.9%-13.1%) in dogs receiving the test diet vs 8.8% (95% CI, 5.1%-12.5%) in dogs receiving control diet (P = .79). Neither component of the primary outcome measure was significantly different between groups (LAD, P = .65; LVIDd, P = .92). No difference was found in mitral valve E wave velocity (P = .36) or the proportion of dogs withdrawn from the study because of worsening DMVD and heart enlargement (P = .41). Conclusions and Clinical Importance: Feeding a specially formulated diet for 365 days was not associated with a significantly different rate of change of left heart size in dogs with subclinical DMVD as compared to control.
- 1 July 2023
- Published by Oxford University Press (OUP) in Journal of Veterinary Internal Medicine
- Vol. 37 (4) , 1323-1330
Open AccessEffect of a specially formulated diet on progression of heart enlargement in dogs with subclinical degenerative mitral valve disease
Background: Previous studies in dogs with degenerative mitral valve disease (DMVD) have identified altered myocardial energy metabolism and oxidation, which might contribute to cardiac hypertrophy. Diets rich in medium chain fatty acids and antioxidants are a potential means of treatment. A previous clinical study found significantly smaller left atrial diameter (LAD) and left atrium-to-aorta diameter ratio (LA : Ao) in dogs with subclinical DMVD fed a specially formulated diet vs control diet for 6 months. Hypothesis/Objectives: A specially formulated diet will slow or arrest left heart enlargement in dogs with subclinical DMVD over 365 days. Animals: One hundred twenty-seven dogs with unmedicated subclinical DMVD; 101 dogs in the per protocol cohort. Methods: Randomized double-blinded controlled multicenter clinical trial. Results: The study's primary composite outcome measure was the sum of percentage change in LAD and left ventricular internal dimension at end-diastole (LVIDd) at day 365. In the per protocol cohort, the outcome measure increased by 8.0% (95% confidence interval [CI], 2.9%-13.1%) in dogs receiving the test diet vs 8.8% (95% CI, 5.1%-12.5%) in dogs receiving control diet (P = .79). Neither component of the primary outcome measure was significantly different between groups (LAD, P = .65; LVIDd, P = .92). No difference was found in mitral valve E wave velocity (P = .36) or the proportion of dogs withdrawn from the study because of worsening DMVD and heart enlargement (P = .41). Conclusions and Clinical Importance: Feeding a specially formulated diet for 365 days was not associated with a significantly different rate of change of left heart size in dogs with subclinical DMVD as compared to control.